Rd

Rob de Ree

CEO at NorthSea Therapeutics B.V.

Amsterdam, North Holland

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $1,000,000.00

  • Target Investment:

    $500,000.00

Skills

Cardiology
Market Development
Product Launch
Capital Equipment
Vascular
Sales Management
Product Development
Marketing Management
Product Marketing
Disposables
Surgeons
Commercialization
Cross-functional Team Leadership
Global Marketing
Healthcare
International Sales
Pharmaceutical Industry
Product Management
Sales Effectiveness
Start-ups

Education

Lists including Rob

AM
Al
AF
AV

Based in Amsterdam

273 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

NorthSea Therapeutics

Series A

Total Funding: $150M

SurgVision

Series Unknown

Total Funding:

Work Experience

DC
Dutch CardioVascular Alliance

2018

  • Chair valorisation DCVA

    2018

NT
NorthSea Therapeutics

2017

  • CEO

    2017

Biogeneration Ventures

2016

  • Operating Partner

    2016

Mellon Medical B.V.

2014 - 2024

  • Member of the Supervisory Board

    2014 - 2024

VM
Ventinova Medical

2015 - 2017

  • Chairman of the Supervisory Board

    2015 - 2017

A
Amgen

2015 - 2016

  • general manager Dezima Pharma

    2015 - 2016

    Dezima Pharma has been acquired by Amgen

Dezima pharma

2013 - 2015

  • CEO

    2013 - 2015

    Dezima Pharma develops innovative drugs in the field of dyslipidemia.

EL
Edwards Lifesciences

2012 - 2013

  • Vice President Critical Care non-invasive

    2012 - 2013

    BMEYE BV has been acquired by Edwards Lifesciences

BMEYE

2007 - 2012

  • CEO

    2008 - 2012

  • VP sales & marketing

    2007 - 2008

C
Crucell

2006 - 2007

  • Sr. Director Business Development

    2006 - 2007